Clinical Trial Update: Efficacy and Safety of Riociguat in Incipient Pulmonary Vascular Disease as an Indicator for Early PAH [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on the efficacy and safety of riociguat for incipient pulmonary vascular disease as an early indicator for pulmonary arterial hype…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Connective Tissue Disease-associated Pulmonary Arterial Hypertension
• Pulmonary Arterial Hypertension
• Systemic Sclerosis-associated Pulmonary Arterial Hypertension

Drugs mentioned

• Adempas (riociguat)
• Riociguat (riociguat)

Snippet

Sponsor: Heidelberg University | Conditions: Pulmonary Vascular Disorder, Primary Pulmonary Hypertension | Phase 2 | Status: TERMINATED | Results posted: 2026-01-21